Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of ARGX-113-1802 with subcutaneous efgartigimod PH20 in CIDP
jRCT2051210001Phase 3Completed
- Sponsor
- argenx
- Start
- Apr 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa + hyaluronidase-qvfc in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by argenx. Primary endpoint: Safety and tolerability of efgartigimod PH20 SC. Started Apr 2021; status: completed.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on jRCT2051210001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210001.